

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

FHL/SEC/STEX/RR/2018-19

May 1, 2018

**The National Stock Exchange of India Ltd.
Corporate Communications Department
“Exchange Plaza”, 5th Floor, Bandra-Kurla
Complex, Bandra (East), Mumbai - 400051
Scrip Symbol: FORTIS**

**BSE Limited
Corporate Services Department,
Phiroze Jeejeebhoy Towers Dalal
Street, Mumbai – 400 001
Scrip Code:532843**

Sub: Regulation 30 Update – IHH’s Enhanced Revised Proposal

Dear Sir(s),

This is in continuation to our letter Ref. No. FHL/SEC/STEX/RR/2018-19 dated April 24, 2018 whereby, it was informed that the Board of Directors of Fortis Healthcare Limited (“**the Company**”) has received Revised Offer from IHH Healthcare Berhad (“**IHH**”) with a proposal to invest in the Company.

It is hereby informed that the Company today i.e. May 1, 2018, has received an Enhanced Revised Proposal, as attached herewith, from IHH to invest directly into the Company at a per share price of INR 175.

We will keep the stock exchanges updated/informed in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records please. We assure you of our full cooperation at all times.

You are kindly requested to take the same on record.

Thanking you,
Yours faithfully

For Fortis Healthcare Limited

**Rahul Ranjan
Company Secretary
M. No. ACS 17035
Encl: a/a**



IHH Healthcare Berhad

1 May 2018

The Board of Directors ("**Board**")
Fortis Healthcare Limited
Tower A, Unitech Business Park
Block F, South 1, Sector 41
Gurugram, Haryana 122001
India

CC:

- (i) Deepak Kapoor, Chair, Expert Advisory Committee ("**EAC**")
- (ii) Lalit Bhasin, Expert Advisory Committee
- (iii) Bhavdeep Singh, CEO
- (iv) Rahul Ranjan, Company Secretary

Dear Directors:

We refer to our letter dated 24 April 2018 ("**Revised IHH Proposal Letter**") setting out the Revised IHH Proposal. We now write to you in continuation of our Revised IHH Proposal. All capitalized terms used herein shall have the meanings ascribed to such terms in the Revised IHH Proposal Letter unless separately defined hereunder.

We now wish to reiterate our seriousness and commitment to an investment in the Company by enhancing the Revised IHH Proposal ("**Enhanced Revised IHH Proposal**") as set forth below:

- (i) The Immediate Equity Infusion shall be at a per share price of INR 175.
- (ii) The Subsequent Equity Infusion shall be at a per share price not exceeding INR 175. For avoidance of doubt, this subsequent equity infusion will be subject to satisfactory completion of the due diligence and execution of mutually acceptable binding definitive documents.

As indicated earlier, we wish to reiterate that we remain flexible to discussing with and jointly working with the Company's Board, the EAC and existing shareholders of the Company towards identifying such other mutually-beneficial instruments, including but not limited to a preferential allotment, rights issue, a combination and/or other optimal means of solving the Company's funding requirements.

Save as set out herein, all other terms and conditions set out under the Revised IHH Proposal Letter shall continue to be applicable to the Enhanced Revised IHH Proposal and this letter must always be read together with the Revised IHH Proposal Letter.

We would like to reiterate that IHH, as a long term strategic investor, is best placed to fund, guide, support and drive the Company forward to realize its potential to the fullest and generate value for all stakeholders.

Please let us hear from you at your earliest convenience and in any event by no later than 5pm IST on 15 May 2018, after which the Enhanced Revised IHH Proposal (i.e., the Revised IHH Proposal Letter read with the terms of this letter) shall stand withdrawn. Our leadership team would be keen to meet with the Board and the Expert Advisory Committee to discuss the Enhanced Revised IHH Proposal and outline our vision for the partnership with Fortis.

IHH Healthcare Berhad (901914V)

Level 11 Block A, Pantai Hospital Kuala Lumpur, 8 Jalan Bukit Pantai, 59100 Kuala Lumpur, Malaysia
Tel: 603 2298 9898 Fax: 603 2298 9899



IHH Healthcare Berhad

Notwithstanding anything in this letter, given the ever-changing competitive dynamics, IHH reserves the right to pursue all necessary steps to ensure that the shareholders of the Company are provided with the opportunity to realize the value inherent in our proposal including the right to revise the offer price in any manner, as IHH deems fit.

Please note that IHH is obliged under applicable law and stock exchange listing rules to release the contents of this letter to Bursa Malaysia and Singapore Exchange Securities Trading Limited immediately.

We look forward to a favourable response.

Sincerely yours,

**For and on behalf of
IHH Healthcare Berhad**

Dr Tan See Leng
Managing Director and Group Chief Executive Officer